차세대 항체 치료제 시장(제2판) - 업계 동향과 세계 예측(-2035년) - 약제별, 신규 항체별, 표적 질환별, 치료법별, 투여 경로별, 주요 지역별, 주요 기업별

Next Generation Antibody Therapeutics Market (2nd Edition): Industry Trends and Global Forecasts, Till 2035 - Distribution by Drug, Novel Antibody, Target Indication, Therapy, Route of Administration, Key Geographical Regions and Leading Players

US $ 4,799 ￦ 6,996,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,204,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,453,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,242,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

차세대 항체 치료제 시장

차세대 항체 치료제 시장 규모는 현재 8억 4,300만 달러에서 2035년까지 21억 6,100만 달러로 성장하며, 예측 기간(-2035년)의 CAGR은 9.87%로 추정되고 있습니다.

시장 규모 및 기회 분석은 다음과 같은 매개 변수별로 분류됩니다.

의약품

• 아드세트리스
• 카도실라
• 엘존리스
• 베스폰사
• 림피아
• 피브로문
• 니드레지
• 이오맙-B
• TLX 591

신규 항체 유형

• 방사성 면역 복합체
• 면역 사이토카인
• 면역독소

대상 적응증

• 치료받지 않은 전신성 미분화 대세포 림프종(SALCL) 또는 기타 CD30 발현 말초 T세포 림프종(PTCL)
• 고전적 호지킨 림프종
• 원발성 피부형 미분화 대세포 림프종(pcALCL) 또는
• CD30을 발현하는 균상호흡기육종(MF)
• 미만성 대세포 B세포 림프종
• 재발성 또는 난치성 B세포 전구세포 급성 질환
• 림프모구백혈병
• HER2 양성 유방암
• 모세포성 형질세포 유사 수지상 세포 신생물
• 국소 진행성 흑색종/III기 B/C 흑색종
• 재발성 또는 난치성 피부 T세포 림프종
• 재발성 또는 불응성 급성 골수성 백혈병 환자
• 백혈병
• 전이성 거세 저항성 전립선암
• 연부조직육종

치료 유형

• 병용요법
• 단독요법

투여 경로

• 종양내 투여
• 정맥내

지역적 지역

• 북미
• 유럽
• 아시아태평양
• 중동 및 아프리카

차세대 항체 치료제 시장 : 성장과 동향

항체(면역글로불린)는 면역체계에 의해 생성되는 단백질로, 세포나 조직의 특정 항원 마커를 식별하고 결합하여 다양한 질병에 대한 주요 방어기능을 수행합니다. 항체와 항원의 정확한 상호작용을 활용한 혁신적인 항체 치료는 환자의 치료 결과를 개선하는 데 큰 가능성을 보여주고 있습니다. 최근 수년간 수많은 혁신적인 항체 치료제가 미국 식품의약국(USFDA)의 승인을 받아 대사 장애, 심혈관 질환, 암, 희귀질환 등 다양한 질환의 치료에서 괄목할 만한 진전을 보이고 있습니다. 이번 승인은 중요한 의료 문제를 해결하는 생명공학 기법의 유효성을 입증하는 동시에 현대 의학에서 항체 치료의 역할을 강조하고 있습니다. 다양한 질환을 대상으로 한 신규 항체 연구개발을 위해서는 자금 조달과 투자 확대, 그리고 공동 연구 노력이 필수적입니다. 또한 수많은 첨단 기술들이 새로운 치료법의 발견과 개발을 혁신적으로 변화시키고 있으며, 치료 접근법을 근본적으로 바꾸고 있습니다.

차세대 항체치료제 시장 : 주요 연구 결과

이 보고서는 세계 차세대 항체 치료제 시장의 현황을 상세하게 분석하고, 업계내 잠재적인 성장 기회를 파악하고 있습니다. 보고서의 주요 내용은 다음과 같습니다.

• 다양한 질병을 치료하기 위해 70여 종의 방사성 면역 복합체가 승인되었거나 개발 단계에 있거나 연구 중에 있습니다. 이 중 80% 이상의 치료제가 개발 초기 단계에 있습니다.

• 단일 요법의 약 70%는 정맥내 투여가 가능하며, 그 중 대다수(96%)의 치료법이 임상 개발 단계에 있습니다.
• 현재 35종 이상의 면역 사이토카인이 다양한 질환의 치료를 목적으로 승인되었거나 개발 단계에 있습니다. 그 중 약 60%의 치료법이 초기 개발 단계에 있습니다.
• 현재 개발 초기 단계에 있는 면역 사이토카인의 45% 이상이 IL-2와 IL-15 유형의 사이토카인과 결합하고 있습니다. 이 중 대다수(80%)의 치료법은 병용요법으로 투여할 수 있습니다.
• 현재 약 60여 종의 면역독소가 다양한 질환의 치료를 위해 승인되었거나 개발 단계에 있는 다양한 면역독소들이 연구되고 있습니다. 그 중 45% 이상의 치료제가 개발 초기 단계에 있습니다.
• 현재 후기 단계(II상 및 II/III상) 면역항암제의 약 80%가 주사로 투여되고 있습니다. 또한 56%의 면역독소는 미생물 독소와 결합되어 있습니다.
• 대부분의 임상시험은 2024년에 등록되었습니다. 특히 주목할 만한 점은 전체 임상시험의 72%라는 상당한 비율이 차세대 항체치료제 연구를 위해 현재 환자를 모집하고 있다는 점입니다.
• 증가하는 과학 문헌은 차세대 항체 치료제 연구개발에 대한 이해관계자들의 적극적인 참여를 강조하고 있으며, 논문의 약 35%가 전년도에 발표되었습니다.
• 특허권자의 대부분은 비산업계 관계자들입니다. 그러나 지난 수년간 업계 관계자들의 특허 출원 활동에 대한 기여도도 증가하고 있습니다.

• 이 분야에서 체결된 계약의 약 20%는 공급 계약이며, 그 중 44%는 신규 항체에 대한 수요 증가에 대응하기 위해 2022년에 체결된 계약입니다.
• 당사의 독자적인 예측 모델을 사용하여 과거 동향, 데이터 및 철저한 조사를 통해 얻은 정보를 고려하여 세계 차세대 항체 치료제 시장의 현재 규모를 추정했습니다.

• 현재 전 세계 차세대 항체 치료제 시장은 HER2 양성 유방암 치료제들이 주도하고 있으며, 그 뒤를 이어 고전적 호지킨림프종

차세대 항체 치료제 시장 : 주요 부문

차세대 항체치료제 시장에서 애드세트리스, 최대 점유율 확보

현재 애드세트리스는 조기 승인과 혈액암에 대한 입증된 효과로 약 45%의 높은 시장 점유율을 차지하고 있습니다. LYMPHIR은 예측 기간 중 18%의 높은 CAGR로 성장할 것으로 예측됩니다.

차세대 항체치료제 시장 점유율의 대부분을 차지하는 면역독소 분야

차세대 항체치료제 시장 예측에 따르면 면역독소 부문이 올해 높은 점유율을 차지하는 배경에는 우수한 표적 세포독성과 내성 암세포에 대한 효능이 있습니다. 또한 면역 사이토카인 분야는 예측 기간 중 40% 이상의 가장 큰 성장 잠재력을 보일 것으로 예측됩니다.

차세대 항체 치료제 시장에서 HER2-PBC가 가장 큰 점유율을 차지하고 있습니다.

올해 HER2-PB는 차세대 항체치료제 시장에서 약 45%라는 큰 시장 점유율을 차지하고 있습니다. 이는 HER2 양성 유방암의 발생률 증가와 환자의 치료 성적과 생존율을 크게 향상시키는 표적치료제의 사용 확대에 기인합니다. 재발성 또는 난치성 피부 T세포 림프종 부문은 예측 기간 중 약 20%의 가장 큰 성장 잠재력을 보일 것으로 예측됩니다.

차세대 항체치료제 업계에서는 단일제 요법이 주류를 이루고 있습니다.

단독요법 부문은 부작용이 적고 높은 특이적 표적화를 실현할 수 있으며, 올해 시장 점유율의 대부분을 차지하고 있습니다. 병용요법 부문은 예측 기간 중 약 45%로 가장 높은 성장 잠재력을 보일 것으로 예측됩니다.

정맥 투여 경로가 차세대 항체치료제 시장 점유율을 주도할 것으로 전망

현재 정맥 투여 경로가 시장을 독점하고 있습니다. 이는 대형 항체를 효과적으로 전달하기 위해 필요한 빠른 작용 발현과 생체 이용률 향상을 실현할 수 있기 때문입니다. 종양내 투여는 더 높은 국소 약물 농도를 달성하고, 전신 독성을 감소시키며, 치료 효과를 높이는 능력에 힘입어 더 높은 CAGR로 확대될 것으로 예측됩니다.

향후 수년간 북미가 차세대 항체 치료제 시장을 주도할 전망

당사의 차세대 항체 치료제 시장 보고서에 따르면 북미는 올해 시장 점유율의 대부분(64%)을 차지할 것으로 예상되며, 이러한 추세는 앞으로도 변함없이 유지될 것으로 보입니다. 이는 탄탄한 의료 시스템, 신규 항체 치료제 개발을 위한 혁신적인 플랫폼, 그리고 맞춤형 의료에 대한 집중적인 노력으로 인해 이 지역이 신규 항체 치료의 최전선에 위치하고 있기 때문입니다.

차세대 항체치료제 시장의 대표적인 기업 사례

• Actinium Pharmaceuticals
• Pfizer
• Philogen
• Roche
• Telix Pharmaceuticals
• Y-mAbs Therapies

신규 항체 치료제 시장 : 조사 범위

• 시장 규모 및 기회 분석 : 이 보고서는 차세대 항체 치료제 시장에 대해(A) 약물,(B) 신규 항체 유형,(C) 적응증,(D) 치료법 유형,(E) 투여 경로,(F) 주요 기업 등 주요 시장 부문에 초점을 맞추어 상세하게 분석했습니다.
• 시장현황1: 방사성 면역복합체(RIC)의 현재 시장현황을(A)개발단계,(B)치료법 유형,(C)투여경로,(D)투여빈도,(E)방사성동위원소 유형,(F)투여방법,(G)작용기전,(H)치료영역,(I)설립연도,(J)기업규모,(K)본사 소재지,(L)개발자 유형,(M)가장 활발하게 진입한 기업.
• 시장 상황 2: 면역 사이토카인의 현재 시장 상황에 대한 상세한 평가와 함께(A)개발 단계,(B)사이토카인 유형,(C)치료법 유형,(D)투여 빈도,(E)작용기전,(F)투여 경로,(G)항원 유형/형태,(H)투여 경로,(I)치료영역,(J)설립연도,(K)기업규모,(L)본사 소재지,(M)개발자 유형,(N)가장 활발하게 진입한 기업.
• 시장 상황3: 면역독소의 현재 시장 상황에 대한 상세한 평가와 함께(A)개발 단계,(B)독소 유형,(C)투여 빈도,(D)치료법 유형,(E)투여 방법,(F)표적 유형,(G)작용기전,(H)투여 경로,(I)치료 영역,(J)설립연도,(K)기업규모,(L)본사 소재지,(M)개발자 유형,(N)주요 진입기업.
• 기업 개요: 북미, 유럽, 아시아태평양에 기반을 두고 차세대 항체 치료제 개발에 참여하고 있는 주요 기업의 상세한 프로파일을 소개합니다. 각 프로파일에는(A) 기업 개요,(B) 재무 정보,(C) 의약품 포트폴리오 세부 정보,(D) 최근 동향,(E) 미래 전망 등이 포함됩니다.
• 임상시험 분석 : 다양한 차세대 항체 치료제를 조사하는 완료 및 진행 중인 임상시험에 대해(A) 임상시험 등록 연도,(B) 임상시험 현황,(C) 임상시험 단계,(D) 등록 환자 수,(E) 연구 설계 및 환자 성별,(F) 스폰서/협조자 기관 유형,(G)가장 활발한 산업,(H)지역적 분포.
• 출판물 분석 : 차세대 항체 치료제 연구와 관련된 다양한 학술 논문을 심층적으로 검토했습니다. 관련 매개변수(예:(A) 출판 연도,(B) 출판물 유형,(C) 주요 출판사,(D) 주요 학술지)를 기반으로 합니다.
• 특허 분석 : 차세대 항체치료제 관련 출원 및 등록된 각종 특허에 대한 상세 분석. A) 공개 연도,(B) 특허 유형,(C) 출원인 유형,(D) 출원 연도,(E) 특허 관할권, 특허 경과 기간,(F) CPC 분류 기호,(G) 주요 진출기업.
• 제휴/협력관계: 유전자치료제, 비바이러스 벡터, 바이러스 벡터 제조 시장에서 구축된 제휴/협력관계에 대해(A)제휴 연도,(B)제휴 형태,(C)제휴처 유형,(D)가장 활발한 진출기업 등 다양한 관련 파라미터를 기반으로 한 인사이트 분석을 제공합니다.
• 대형 제약사: 차세대 항체치료제 분야에 참여하는 대형 제약사에 대해(A) 개발력,(B) 포트폴리오의 강점,(C) 포트폴리오의 다양성 등 여러 관련 파라미터를 기준으로 분석.
• 최근 확장 동향 : 바이러스 벡터 및 비바이러스 벡터 생산 능력 강화를 위해 각 사가 실시한 최근 확장 동향을(A) 확장 실시 연도,(B) 확장 유형,(C) 벡터 유형,(D) 응용 분야,(E) 확장 지역 등 여러 매개 변수를 기준으로 분석합니다.
• 시장 영향 분석 : 유전자 치료, 비바이러스 벡터 및 바이러스 벡터 제조 시장의 성장에 영향을 미칠 수 있는 요인에 대한 상세한 분석입니다. 또한(A) 주요 촉진요인,(B) 잠재적 제약 요인,(C) 새로운 기회,(D) 기존 과제 파악 및 분석도 포함됩니다.

목차

제1장 배경

제2장 조사 방법

제3장 시장 역학

제4장 거시경제 지표

• 시장 역학

제5장 개요

제6장 서론

• 차세대 항체 치료제의 개요
• 치료 용항체 : 개발 어프로치
• 향후 전망

제7장 경쟁 구도 : 신규 항체 치료제(방사성 동위 원소 면역 복합체)

• 챕터 개요
• 시장 구도 : 방사성 동위 원소 면역 복합체
• 개발자 전망 : 방사성 동위 원소 면역 복합체

제8장 경쟁 구도 : 신규 항체 치료제(면역 사이토카인)

• 챕터 개요
• 시장 구도 : 면역 사이토카인
• 개발자 전망 : 면역 사이토카인

제9장 경쟁 구도 : 신규 항체 치료제(면역독소)

• 챕터 개요
• 시장 구도 : 면역독소
• 개발자 환경 : 면역독소

제10장 신규 항체 개발자

• 챕터 개요
  • Actinium Pharmaceuticals
  • Pfizer
  • Philogen
  • Roche
  • Telix Pharmaceuticals
  • Y-mAbs Therapeutics

제11장 임상시험 분석

• 분석 조사 방법과 주요 파라미터
• 시험 등록 연별 분석
• 시험 상황별 분석
• 시험 등록년과 시험 상황별 분석
• 시험 등록 연별로 등록된 환자의 분석
• 시험 상황 별로 등록된 환자의 분석
• 시험 단계별 분석
• 연구 디자인별 분석
• 대상 환자 집단별 분석

제12장 출판물 분석

• 분석 조사 방법과 주요 파라미터
• 차세대 항체 치료제 : 출판물 분석

제13장 특허 분석

• 분석 조사 방법과 주요 파라미터
• 차세대 항체 치료제 : 특허 분석

제14장 파트너십과 협업

제15장 대형 제약회사

• 분석 조사 방법과 주요 파라미터
• 차세대 항체 치료제 분야에서 대형 제약 기업 리스트
• 주요 파라미터 채점 기준

제16장 시장 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제17장 세계의 차세대 항체 치료제 시장

제18장 차세대 항체 치료제 시장(약제별)

제19장 차세대 항체 치료제 시장(신규 항체 유형별)

제20장 차세대 항체 치료제 시장(표적 질환별)

제21장 차세대 항체 치료제 시장(치료법별)

제22장 차세대 항체 치료제 시장(투여 경로별)

제23장 차세대 항체 치료제 시장(주요 지역별)

제24장 시장 기회 분석 : 북미

제25장 시장 기회 분석 : 유럽

제26장 시장 기회 분석 : 아시아태평양

제27장 시장 기회 분석 : 중동·북아프리카

제28장 차세대 항체 치료제 시장(주요 기업별)

제29장 표형식 데이터

제30장 기업·단체 리스트

KSA

영문 목차

영문목차

Next Generation Antibody Therapeutics Market

As per Roots Analysis, the next generation antibody therapeutics market is estimated to grow from USD 843 million in the current year to USD 2,161 million by 2035, at a CAGR of 9.87% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Drugs

• Adcetris
• Kadcyla
• ELZONRIS
• Besponsa
• LYMPHIR
• Fibromun
• Nidlegy
• Iomab-B
• TLX 591

Type of Novel Antibody

• Radioisotope Immunoconjugates
• Immunocytokines
• Immunotoxins

Target Indication

• Previously Untreated Systemic Anaplastic Large Cell Lymphoma (SALCL) or other CD30-expressing Peripheral T-cell Lymphomas (PTCL)
• Classical Hodgkin Lymphoma
• Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or
• CD30-expressing Mycosis Fungoides (MF)
• Diffuse Large B-cell Lymphoma
• Relapsed or Refractory B-cell precursor Acute
• Lymphoblastic Leukemia
• HER2-positive breast cancer
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Locally Advanced, Melanoma / Stage III B / C Melanoma
• Relapsed or Refractory Cutaneous T-cell Lymphoma
• Relapsed / Refractory Acute Myeloid
• Leukemia
• Metastatic Castration-resistant Prostate Cancer
• Soft Tissue Sarcoma

Type of Therapy

• Combination Therapy
• Monotherapy

Route of Administration

• Intratumoral
• Intravenous

Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa

Novel Antibody Therapies Market: Growth and Trends

Antibodies, or immunoglobulins, are proteins generated by the immune system that identify and attach to particular antigen markers on cells or tissues, acting as the primary defense against various ailments. Utilizing the accuracy of antibody-antigen interactions, innovative antibody treatments have shown considerable promise in enhancing patient results. In recent years, numerous innovative antibody treatments received approval from the USFDA, signifying notable progress in the treatment of a range of illnesses, such as metabolic disorders, cardiovascular issues, cancer, and rare diseases. These authorizations demonstrate the effectiveness of biotechnological methods in tackling significant healthcare issues and underscore the role of antibody therapies in contemporary medicine. Increased funding and investments, along with partnership initiatives, are vital for the research and development of new antibodies targeting various disorders. Moreover, numerous advanced technologies are transforming the identification and development of new therapies, fundamentally changing treatment approaches.

Novel Antibody Therapies Market: Key Insights

The report delves into the current state of the global novel antibody therapies market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Over 70 radioisotope immunoconjugates are approved / being investigated across different stages of development for the treatment of various diseases; of these, >80% of the therapies are in early-stages of development.

• Close to 70% of the monotherapies can be administered intravenously; of these, majority (96%) of the therapies are under clinical stages of development.
• Over 35 immunocytokines are currently approved / being investigated across various stages of development for the treatment of various diseases; of these, nearly 60% of the therapies are in early-stages of development.
• Presently, over 45% of immunocytokines in early stages of development are in conjugation with IL-2 and IL-15 types of cytokine; of these, majority (80%) of the therapies can be administered as combination therapy.
• Nearly 60 immunotoxins are currently approved / being investigated across different stages of development for the treatment of various diseases; of these, more than 45% of the therapies are in early-stages of development.
• Presently, nearly 80% of the late-stage immunotoxins (phase II and phase II / III) are administered via injections; further, 56% immunotoxins are in conjugation with microbial toxins.
• Most of the trials were registered in 2024; notably, a significant proportion (72%) of the total trials are currently recruiting patients for the investigation of novel antibody therapies.
• The growing scientific literature highlights the active involvement of stakeholders in the research and development of novel antibody therapies; close to 35% of the articles were published in the previous year.
• Majority of the patent assignees are non-industry players; however, over the past few years, the contribution of industry players in the patent filing activity has also increased.

• Close to 20% deals inked in this domain are supply agreements; of these, 44% agreements were signed in 2022 in order to address the growing demand for novel antibodies.
• Using our proprietary forecast model, we estimated the current size of the global novel antibody therapies market, taking into consideration the historical trends, data and inputs obtained from exhaustive research.

• Currently, the global novel antibody therapies market is dominated by drugs that are intended to target HER2-positive breast cancer, followed by classical Hodgkin lymphoma.

Novel Antibody Therapies Market: Key Segments

Adcetris Drug Captures the Largest Share in the Next Generation Antibody Therapeutics Market

Currently, Adcetris holds the higher market share of close to 45% due to its early approvals and proven effectiveness in hematologic cancers. LYMPHIR is expected to expand at an increased CAGR of 18% throughout the forecast period.

Immunotoxins Segment Holds the Majority of the Next Generation Antibody Therapeutics Market Share

The higher share of immunotoxins segment in the current year can be attributed to their superior targeted cytotoxicity and effectiveness against resistant cancer cells, as per next generation antibody therapeutics market forecast. Further, the immunocytokines sector is expected to exhibit the greatest growth potential, of over 40%, throughout the forecast period.

HER2-PBC Hold the Largest Share in the Next Generation Antibody Therapeutics Market

In the present year, HER2-PB captures a significant market share of nearly 45% in novel antibody therapies, driven by the growing incidence of HER2-positive breast cancer and the heightened use of targeted treatments that lead to substantial enhancements in patient outcomes and survival rates. The segment for relapsed or refractory cutaneous T-cell lymphoma is expected to exhibit the greatest growth potential of nearly 20% throughout the forecast period.

Monotherapy Dominates Next Generation Antibody Therapies Industry

Monotherapy segment holds most of the market share in the current year owing to its ability to provide highly specific targeting with fewer side effects. The combination therapy segment is likely to show the highest growth potential of close to 45%, during the forecast period.

Intravenous Route of Administration Dominates Next Generation Antibody Therapeutics Market Share

Currently, intravenous route of administration, the intravenous method dominates the market due to its capacity to provide a quick onset of action and improved bioavailability needed for effectively delivering large antibodies. The intratumoral method of delivery is expected to expand at a higher CAGR, fueled by its capacity to attain greater local drug levels, reduce systemic toxicity, and enhance treatment effectiveness

North America is Likely to Propel in the Next Generation Antibody Therapeutics Market in the Coming Years

According to our next generation antibody therapeutics market report, North America is likely to capture the majority (64%) of the market share in the current year, and this trend is unlikely to change in the future. This can be attributed to the strong healthcare system, innovative platforms for developing new antibody treatments, and a significant emphasis on personalized care, positioning this region at the forefront of novel antibody treatments.

Example Players in the Next Generation Antibody Therapeutics Market

• Actinium Pharmaceuticals
• Pfizer
• Philogen
• Roche
• Telix Pharmaceuticals
• Y-mAbs Therapies

Novel Antibody Therapies Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the novel antibody therapies market, focusing on key market segments, including [A] drug, [B] type of novel antibody, [C] target indication, [D] type of therapy, [E] route of administration and [F] leading players.
• Market Landscape 1: A detailed assessment of the current market landscape of radioisotope immunoconjugates, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of therapy, [C] route of administration, [D] dosing frequency, [E] type of radioisotope, [F] mode of administration, [G] mechanism of action [H] therapeutic area, [I] year of establishment, [J] company size, [K] location of headquarters, [L] type of developer and [M] most active players.
• Market Landscape 2: A detailed assessment of the current market landscape of immunocytokines, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of cytokine, [C] type of therapy, [D] dosing frequency, [E] mechanism of action, [F] mode of administration, [G] type of antigen / format, [H] route of administration [I] therapeutic area, [J] year of establishment, [K] company size, [L] location of headquarters, [M] type of developer and [N] most active players.
• Market Landscape 3: A detailed assessment of the current market landscape of immunotoxins, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of toxin, [C] dosing frequency, [D] type of therapy, [E] mode of administration, [F] type of target, [G] mechanism of action, [H] route of administration, [I] therapeutic area, [J] year of establishment, [K] company size, [L] location of headquarters, [M] type of developer and [N] most active players.
• Company Profiles: In-depth profiles of prominent players based in regions, namely North America, Europe and Asia-Pacific that are currently involved in the engaged in the development of novel antibody therapies. Each profile features [A] a brief overview of the company, [B] its financial information, [C] details on its drug portfolio, [D] recent developments and an [E] informed future outlook.
• Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating different novel antibody therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] study design, patient gender, [F] type of sponsor / collaborator, [G] most active industry and [H] geographical distribution.
• Publication Analysis: A detailed review of various peer-reviewed, scientific articles related to research on novel antibody therapies, based on relevant parameters, such as [A] year of publication, [B] type of publication, [C] popular publisher and [D] key journal.
• Patent Analysis: in-depth analysis of various patents that have been filed / granted for novel antibody therapies, taking into consideration parameters, such as [A] publication year, [B] type of patent, [C] type of applicant, [D] application year, [E] patent jurisdiction, patent age, [F] CPC symbols, [G] leading players.
• Partnerships and Collaborations An insightful analysis of the partnerships and collaborations established in gene therapy, non viral vector and viral vector manufacturing market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
• Big Pharma Players: An analysis of big pharma players engaged in the field of novel antibody therapies, based on several relevant parameters, such as [A] developer strength, [B] portfolio strength, and [C] portfolio diversity.
• Recent Expansions: An analysis of the recent expansions undertaken by various companies in order to augment their respective capabilities related to viral vector and non viral vector manufacturing, based on several parameters, such as [A] year of expansion, [B] type of expansion, [C] type of vector, [D] application area and [E] geographical location of the expansion.
• Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of gene therapy, non viral vector and viral vector manufacturing market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What is the current global capacity of developers?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2. RESEARCH METHODOLOGY

• 2.1. Research Assumptions
  • 2.1.1. Market Landscape and Market Trends
  • 2.1.2. Market Forecast and Opportunity Analysis
  • 2.1.3. Comparative Analysis
• 2.2. Database Building
  • 2.2.1. Data Collection
  • 2.2.2. Data Validation
  • 2.2.3. Data Analysis
• 2.3. Project Methodology
  • 2.3.1. Project Commencement
  • 2.3.2. Secondary Research
    • 2.3.2.1. Annual Reports
    • 2.3.2.2. Academic Research Papers
    • 2.3.2.3. Company Websites
    • 2.3.2.4. Investor Presentations and Regulatory Filings
    • 2.3.2.5. White Papers
    • 2.3.2.6. Industry Publications
    • 2.3.2.7. Conferences and Seminars
    • 2.3.2.8. Government Portals
    • 2.3.2.9. Media and Press Releases
    • 2.3.2.10. Newsletters
    • 2.3.2.11. Industry and Paid Databases
    • 2.3.2.12. Roots Proprietary Databases
  • 2.3.3. Primary Research
  • 2.3.4. Data Analysis and Interpretation
  • 2.3.5. Market Forecast and Validation
  • 2.3.6. Report Compilation
• 2.4. Research Ethics and Integrity
• 2.5. Analytical Tools and Databases
• 2.6. Robust Quality Control Framework

3. MARKET DYNAMICS

• 3.1. Forecast Methodology
  • 3.1.1. Top-Down Approach
  • 3.1.2. Bottom-Up Approach
  • 3.1.3. Hybrid Approach
• 3.2. Market Assessment Framework
  • 3.2.1. Total Addressable Market (TAM)
  • 3.2.2. Serviceable Addressable Market (SAM)
  • 3.2.3. Serviceable Obtainable Market (SOM)
  • 3.2.4. Currently Acquired Market (CAM)
• 3.3. Forecasting Tools and Techniques
  • 3.3.1. Qualitative Forecasting
  • 3.3.2. Correlation
  • 3.3.3. Regression
  • 3.3.4. Extrapolation
  • 3.3.5. Convergence
  • 3.3.6. Sensitivity Analysis
  • 3.3.7. Scenario Planning
  • 3.3.8. Data Visualization
  • 3.3.9. Time Series Analysis
  • 3.3.10. Forecast Error Analysis
• 3.4. Key Considerations
  • 3.4.1. Demographics
  • 3.4.2. Economic Factors
  • 3.4.3. Competitive Landscape
  • 3.4.4. Government Regulations and Policies
  • 3.4.5. R&D Investment
  • 3.4.6. Technological Factors
  • 3.4.7. Industry Consolidation
  • 3.4.8. Supply Chain
  • 3.4.9. Market Access
  • 3.4.10. Pandemics / Unforeseen Disruptions Impact

4. MACRO-ECONOMIC INDICATORS

• 4.1. Market Dynamics
  • 4.1.1. Time Period
    • 4.1.1.1. Historical Trends
    • 4.1.1.2. Current and Forecasted Estimates
  • 4.1.2. Currency Coverage
    • 4.1.2.1. Overview of Major Currencies Affecting the Market
    • 4.1.2.2. Impact of Currency Fluctuations on the Industry
  • 4.1.3. Foreign Exchange Impact
    • 4.1.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 4.1.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.1.4. Recession
    • 4.1.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.1.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 4.1.5. Inflation
    • 4.1.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.1.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.1.6. Other Indicators
    • 4.1.6.1. War Impact Analysis
    • 4.1.6.2. Cross-border Dynamics
    • 4.1.6.3. Consumer Spendings and Gross Domestic Product
    • 4.1.6.4. Stock Market Performance

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. An Overview of Novel Antibody Therapies
• 6.2. Therapeutic Antibodies: Developmental Approaches
  • 6.2.1. Novel Antibody Therapies: Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
    • 6.2.1.1. Mechanism of Action of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
    • 6.2.1.2. Advantages of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
    • 6.2.1.3. Disadvantages of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
  • 6.2.2. Novel Antibody Therapies: TCR like Antibodies
    • 6.2.2.1. Mechanism of Action of TCR like Antibodies
    • 6.2.2.2. Advantages of TCR like Antibodies
    • 6.2.2.3. Disadvantages of TCR like Antibodies
  • 6.2.3. Novel Antibody Therapies: Radioisotope Immunoconjugates
    • 6.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
    • 6.2.3.2. Advantages of Radioisotope Immunoconjugates
    • 6.2.3.3. Disadvantages of Radioisotope Immunoconjugates
  • 6.2.4. Novel Antibody Therapies: Immunotoxins
    • 6.2.4.1. Mechanism of Action of Immunotoxins
    • 6.2.4.2. Advantages of Immunotoxins
    • 6.2.4.3. Disadvantages of Immunotoxins
  • 6.2.5. Novel Antibody Therapies: Intracellular Antibody
    • 6.2.5.1. Mechanism of Action of Intracellular Antibody
    • 6.2.5.2. Advantages of Intracellular Antibody
    • 6.2.5.3. Disadvantages of Intracellular Antibody
  • 6.2.6. Novel Antibody Therapies: Immunocytokines
    • 6.2.6.1. Mechanism of Action of Immunocytokines
    • 6.2.6.2. Advantages of Immunocytokines
    • 6.2.6.3. Disadvantages of Immunocytokines
• 6.3. Future Perspectives

7. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (RADIOISOTOPE IMMUNOCONJUGATES)

• 7.1. Chapter Overview
• 7.2. Market Landscape: Radioisotope Immunoconjugates
  • 7.2.1. Analysis by Stage of Development
  • 7.2.2. Analysis by Type of Therapy
  • 7.2.3. Analysis by Route of Administration
  • 7.2.4. Analysis by Dosing Frequency
  • 7.2.5. Analysis by Type of Radioisotope
  • 7.2.6. Analysis by Mode of Administration
  • 7.2.7. Analysis by Mechanism of Action
  • 7.2.8. Analysis by Therapeutic Area
• 7.3. Developer Landscape: Radioisotope Immunoconjugates
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters
  • 7.3.4. Analysis by Type of Developer
  • 7.3.5. Most Active Players: Analysis by Number of Therapies

8. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (IMMUNOCYTOKINES)

• 8.1. Chapter Overview
• 8.2. Market Landscape: Immunocytokines
  • 8.2.1. Analysis by Stage of Development
  • 8.2.2. Analysis by Type of Cytokine
  • 8.2.3. Analysis by Type of Therapy
  • 8.2.4. Analysis by Dosing Frequency
  • 8.2.5. Analysis by Mechanism of Action
  • 8.2.6. Analysis by Mode of Administration
  • 8.2.7. Analysis by Type of Antigen / Format
  • 8.2.8. Analysis by Route of Administration
  • 8.2.9. Analysis by Therapeutic Area
• 8.3. Developer Landscape: Immunocytokines
  • 8.3.1. Analysis by Year of Establishment
  • 8.3.2. Analysis by Company Size
  • 8.3.3. Analysis by Location of Headquarters
  • 8.3.4. Most Active Players: Analysis by Number of Therapies

9. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (IMMUNOTOXINS)

• 9.1. Chapter Overview
• 9.2. Market Landscape: Immunotoxins
  • 9.2.1. Analysis by Stage of Development
  • 9.2.2. Analysis by Type of Toxin
  • 9.2.3. Analysis by Dosing Frequency
  • 9.2.4. Analysis by Type of Therapy
  • 9.2.5. Analysis by Mode of Administration
  • 9.2.6. Analysis by Type of Target
  • 9.2.7. Analysis by Mechanism of Action
  • 9.2.8. Analysis by Route of Administration
  • 9.2.9. Analysis by Therapeutic Area
• 9.3. Developer Landscape: Immunotoxins
  • 9.3.1. Analysis by Year of Establishment
  • 9.3.2. Analysis by Company Size
  • 9.3.3. Analysis by Location of Headquarters
  • 9.3.4. Analysis by Type of Developer
  • 9.3.5. Most Active Players: Analysis by Number of Therapies

10. NOVEL ANTIBODY DEVELOPERS

• 10.1. Chapter Overview
  • 10.1.1. Actinium Pharmaceuticals
    • 10.1.1.1. Company Overview
    • 10.1.1.2. Management Team
    • 10.1.1.3. Contact Details
    • 10.1.1.4. Drug Portfolio
    • 10.1.1.5. Recent Developments and Future Outlook
  • 10.1.2. Pfizer
    • 10.1.2.1. Company Overview
    • 10.1.2.2. Management Team
    • 10.1.2.3. Contact Details
    • 10.1.2.4. Operating Business Segments
    • 10.1.2.5. Financial Information
    • 10.1.2.6. Drug Portfolio
    • 10.1.2.7. Recent Developments and Future Outlook
  • 10.1.3. Philogen
    • 10.1.3.1. Company Overview
    • 10.1.3.2. Management Team
    • 10.1.3.3. Contact Details
    • 10.1.3.4. Financial Information
    • 10.1.3.5. Drug Portfolio
    • 10.1.3.6. Recent Developments and Future Outlook
  • 10.1.4. Roche
    • 10.1.4.1. Company Overview
    • 10.1.4.2. Management Team
    • 10.1.4.3. Contact Details
    • 10.1.4.4. Operating Business Segments
    • 10.1.4.5. Financial Information
    • 10.1.4.6. Drug Portfolio
    • 10.1.4.7. Recent Developments and Future Outlook
  • 10.1.5. Telix Pharmaceuticals
    • 10.1.5.1. Company Overview
    • 10.1.5.2. Management Team
    • 10.1.5.3. Contact Details
    • 10.1.5.4. Financial Information
    • 10.1.5.5. Drug Portfolio
    • 10.1.5.6. Recent Developments and Future Outlook
  • 10.1.6. Y-mAbs Therapeutics
    • 10.1.6.1. Company Overview
    • 10.1.6.2. Management Team
    • 10.1.6.3. Contact Details
    • 10.1.6.4. Financial Information
    • 10.1.6.5. Drug Portfolio
    • 10.1.6.6. Recent Developments and Future Outlook

11. CLINICAL TRIAL ANALYSIS

• 11.1. Analysis Methodology and Key Parameters
• 11.2. Analysis by Trial Registration Year
• 11.3. Analysis by Trial Status
• 11.4. Analysis by Trial Registration Year and Trial Status
• 11.5. Analysis of Patients Enrolled by Trial Registration Year
• 11.6. Analysis of Patients Enrolled by Trial Status
• 11.7. Analysis by Trial Phase
• 11.8. Analysis by Study Design
• 11.9. Analysis by Target Patient Population
  • 11.9.1. Analysis by Patient Gender
  • 11.9.2. Analysis by Type of Sponsor / Collaborator
  • 11.9.3. Most Active Industry Players: Analysis by Number of Trials
  • 11.9.4. Analysis of Trials and Number of Patients Enrolled

12. PUBLICATION ANALYSIS

• 12.1. Analysis Methodology and Key Parameters
• 12.2. Novel Antibody Therapies: Publication Analysis
  • 12.2.1. Analysis by Year of Publication
  • 12.2.2. Analysis by Type of Publication
  • 12.2.3. Analysis by Most Popular Publisher
  • 12.2.4. Key Journals: Analysis by Number of Publications
  • 12.2.5. Key Journals: Analysis by Impact Factor

13. PATENT ANALYSIS

• 13.1. Analysis Methodology and Key Parameters
• 13.2. Novel Antibody Therapies: Patent Analysis
  • 13.2.1. Analysis by Publication Year
  • 13.2.2. Analysis by Type of Patent
  • 13.2.3. Analysis of Granted Patents and Patent Applications by Year
  • 13.2.4. Analysis by Type of Applicant
  • 13.2.5. Analysis by Application Year
  • 13.2.6. Analysis by Patent Jurisdiction
  • 13.2.7. Analysis by Patent Age
  • 13.2.8. Leading Industry Players: Analysis by Number of Patents
  • 13.2.9. Leading Non-Industry Players: Analysis by Number of Patents
  • 13.2.10. Leading Individual Assignees: Analysis by Number of Patents
  • 13.2.11. Patent Benchmarking: Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
  • 13.2.12. Patent Benchmarking: Analysis of Leading Industry Players by Patent Characteristics (CPC Codes)
  • 13.2.13. Patent Valuation: Analysis Methodology and Parameters
  • 13.2.14. Patent Valuation: Analysis by Relative Valuation

14. PARTNERSHIPS AND COLLABORATIONS

• 14.1. Chapter Overview
• 14.2. Partnership Models
• 14.3. Novel Antibody Therapeutics: Partnerships and Collaborations
  • 14.3.1. Analysis by Year of Partnership
  • 14.3.2. Analysis by Type of Partnership
  • 14.3.3. Analysis by Year and Type of Partnership
  • 14.3.4. Most Popular Drug: Analysis by Number of Partnerships
  • 14.3.5. Analysis by Types of Novel Antibody
  • 14.3.6. Analysis by Type of Partner
  • 14.3.7. Most Active Players: Analysis by Number of Partnerships
  • 14.3.8. Analysis by Therapeutic Area
  • 14.3.9. Analysis by Therapeutic Area and Type of Partnership
  • 14.3.10. Analysis by Geography
    • 14.3.10.1. Local and International Agreements
    • 14.3.10.2. Intracontinental and Intercontinental Agreements

15. BIG PHARMA PLAYERS

• 15.1. Analysis Methodology and Key Parameters
• 15.2. List of Big Pharma Players in Novel Antibody Therapies Domain
• 15.3. Scoring Criteria for Key Parameters
  • 15.3.1. Analysis by Developer Strength
  • 15.3.2. Analysis by Portfolio Strength
  • 15.3.3. Analysis by Portfolio Diversity
  • 15.3.4. Benchmarking: Spider Web Analysis
  • 15.3.5. Benchmarking: Harvey Ball Analysis
  • 15.3.6. Benchmarking: Wind Rose Chart

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 16.1. Chapter Overview
• 16.2. Market Drivers
• 16.3. Market Restraints
• 16.4. Market Opportunities
• 16.5. Market Challenges

17. GLOBAL NOVEL ANTIBODY THERAPIES MARKET

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Global Novel Antibody Therapies Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 17.4. Multivariate Scenario Analysis
  • 17.4.1. Conservative Scenario
  • 17.4.2. Optimistic Scenario
• 17.5. Key Market Segmentations

18. NOVEL ANTIBODY THERAPIES MARKET, BY DRUGS

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Novel Antibody Therapies Market: Distribution by Drugs
  • 18.3.1. Novel Antibody Therapies Market for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.2. Novel Antibody Therapies Market for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.3. Novel Antibody Therapies Market for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.4. Novel Antibody Therapies Market for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.5. Novel Antibody Therapies Market for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.6. Novel Antibody Therapies Market for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.7. Novel Antibody Therapies Market for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.8. Novel Antibody Therapies Market for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.9. Novel Antibody Therapies Market for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 18.4. Data Triangulation and Validation

19. NOVEL ANTIBODY THERAPIES MARKET, BY TYPE OF NOVEL ANTIBODY

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Novel Antibody Therapies Market: Distribution by Type of Novel Antibody
  • 19.3.1. Novel Antibody Therapies Market for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 19.3.2. Novel Antibody Therapies Market for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 19.3.3. Novel Antibody Therapies Market for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 19.4. Data Triangulation and Validation

20. NOVEL ANTIBODY THERAPIES MARKET, BY TARGET INDICATION

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Novel Antibody Therapies Market: Distribution by Target Indication
  • 20.3.1. Novel Antibody Therapies Market for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.2. Novel Antibody Therapies Market for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.3. Novel Antibody Therapies Market for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.4. Novel Antibody Therapies Market for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.5. Novel Antibody Therapies Market for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.6. Novel Antibody Therapies Market for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.7. Novel Antibody Therapies Market for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.8. Novel Antibody Therapies Market for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.9. Novel Antibody Therapies Market for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.10. Novel Antibody Therapies Market for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.11. Novel Antibody Therapies Market for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.12. Novel Antibody Therapies Market for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 20.4. Data Triangulation and Validation

21. NOVEL ANTIBODY THERAPIES MARKET, BY TYPE OF THERAPY

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Novel Antibody Therapies Market: Distribution by Type of Therapy
  • 21.3.1. Novel Antibody Therapies Market for Monotherapy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 21.3.2. Novel Antibody Therapies Market for Combination Therapy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 21.4. Data Triangulation and Validation

22. NOVEL ANTIBODY THERAPIES MARKET, BY ROUTE OF ADMINISTRATION

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Novel Antibody Therapies Market: Distribution by Route of Administration
  • 22.3.1. Novel Antibody Therapies Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 22.3.2. Novel Antibody Therapies Market for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 22.4. Data Triangulation and Validation

23. NOVEL ANTIBODY THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Novel Antibody Therapies Market: Distribution by Geographical Regions
  • 23.3.1. Novel Antibody Therapies Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.1.1. Novel Antibody Therapies Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.1.2. Novel Antibody Therapies Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.3.2. Novel Antibody Therapies Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.1. Novel Antibody Therapies Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.2. Novel Antibody Therapies Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.3. Novel Antibody Therapies Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.4. Novel Antibody Therapies Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.5. Novel Antibody Therapies Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.3.3. Novel Antibody Therapies Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3.1. Novel Antibody Therapies Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3.2. Novel Antibody Therapies Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3.3. Novel Antibody Therapies Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3.4. Novel Antibody Therapies Market in New Zealand, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.3.4. Novel Antibody Therapies Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4.1. Novel Antibody Therapies Market in Egypt, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4.2. Novel Antibody Therapies Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4.3. Novel Antibody Therapies Market in Iraq, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4.4. Novel Antibody Therapies Market in Morocco, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 23.4. Novel Antibody Therapies Market, By Geographical Regions: Market Dynamics Assessment
  • 23.4.1. Market Movement Analysis
  • 23.4.2. Penetration-Growth (P-G) Matrix
• 23.5. Data Triangulation and Validation

24. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 24.1. Novel Antibody Therapies Market in North America: Distribution by Drugs
  • 24.1.1. Novel Antibody Therapies Market in North America for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.2. Novel Antibody Therapies Market in North America for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.3. Novel Antibody Therapies Market in North America for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.4. Novel Antibody Therapies Market in North America for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.5. Novel Antibody Therapies Market in North America for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.6. Novel Antibody Therapies Market in North America for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.7. Novel Antibody Therapies Market in North America for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.8. Novel Antibody Therapies Market in North America for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.9. Novel Antibody Therapies Market in North America for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 24.2. Novel Antibody Therapies Market in North America: Distribution by Type of Novel Antibody
  • 24.2.1. Novel Antibody Therapies Market in North America for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.2.2. Novel Antibody Therapies Market in North America for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.2.3. Novel Antibody Therapies Market in North America for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 24.3. Novel Antibody Therapies Market in North America: Distribution by Target Indication
  • 24.3.1. Novel Antibody Therapies Market in North America for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.2. Novel Antibody Therapies Market in North America for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.3. Novel Antibody Therapies Market in North America for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.4. Novel Antibody Therapies Market in North America for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.5. Novel Antibody Therapies Market in North America for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.6. Novel Antibody Therapies Market in North America for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.7. Novel Antibody Therapies Market in North America for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.8. Novel Antibody Therapies Market in North America for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.9. Novel Antibody Therapies Market in North America for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.10. Novel Antibody Therapies Market in North America for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.11. Novel Antibody Therapies Market in North America for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.12. Novel Antibody Therapies Market in North America for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 24.4. Novel Antibody Therapies Market in North America: Distribution by Type of Therapy
  • 24.4.1. Novel Antibody Therapies Market in North America for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.2. Novel Antibody Therapies Market in North America for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.5. Novel Antibody Therapies Market in North America: Distribution by Route of Administration
  • 24.5.1. Novel Antibody Therapies Market in North America for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.5.2. Novel Antibody Therapies Market in North America for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25. MARKET OPPORTUNITY ANALYSIS: EUROPE

• 25.1. Novel Antibody Therapies Market in Europe: Distribution by Drugs
  • 25.1.1. Novel Antibody Therapies Market in Europe for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.2. Novel Antibody Therapies Market in Europe for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.3. Novel Antibody Therapies Market in Europe for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.4. Novel Antibody Therapies Market in Europe for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.5. Novel Antibody Therapies Market in Europe for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.6. Novel Antibody Therapies Market in Europe for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.7. Novel Antibody Therapies Market in Europe for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.8. Novel Antibody Therapies Market in Europe for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.9. Novel Antibody Therapies Market in Europe for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 25.2. Novel Antibody Therapies Market in Europe: Distribution by Type of Novel Antibody
  • 25.2.1. Novel Antibody Therapies Market in Europe for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.2.2. Novel Antibody Therapies Market in Europe for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.2.3. Novel Antibody Therapies Market in Europe for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 25.3. Novel Antibody Therapies Market in Europe: Distribution by Target Indication
  • 25.3.1. Novel Antibody Therapies Market in Europe for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.2. Novel Antibody Therapies Market in Europe for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.3. Novel Antibody Therapies Market in Europe for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.4. Novel Antibody Therapies Market in Europe for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.5. Novel Antibody Therapies Market in Europe for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.6. Novel Antibody Therapies Market in Europe for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.7. Novel Antibody Therapies Market in Europe for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.8. Novel Antibody Therapies Market in Europe for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.9. Novel Antibody Therapies Market in Europe for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.10. Novel Antibody Therapies Market in Europe for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.11. Novel Antibody Therapies Market in Europe for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.12. Novel Antibody Therapies Market in Europe for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 25.4. Novel Antibody Therapies Market in Europe: Distribution by Type of Therapy
  • 25.4.1. Novel Antibody Therapies Market in Europe for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.2. Novel Antibody Therapies Market in Europe for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.5. Novel Antibody Therapies Market in Europe: Distribution by Route of Administration
  • 25.5.1. Novel Antibody Therapies Market in Europe for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.5.2. Novel Antibody Therapies Market in Europe for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

• 26.1. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Drugs
  • 26.1.1. Novel Antibody Therapies Market in Asia-Pacific for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.2. Novel Antibody Therapies Market in Asia-Pacific for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.3. Novel Antibody Therapies Market in Asia-Pacific for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.4. Novel Antibody Therapies Market in Asia-Pacific for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.5. Novel Antibody Therapies Market in Asia-Pacific for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.6. Novel Antibody Therapies Market in Asia-Pacific for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.7. Novel Antibody Therapies Market in Asia-Pacific for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.8. Novel Antibody Therapies Market in Asia-Pacific for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.9. Novel Antibody Therapies Market in Asia-Pacific for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 26.2. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Type of Novel Antibody
  • 26.2.1. Novel Antibody Therapies Market in Asia-Pacific for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.2.2. Novel Antibody Therapies Market in Asia-Pacific for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.2.3. Novel Antibody Therapies Market in Asia-Pacific for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 26.3. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Target Indication
  • 26.3.1. Novel Antibody Therapies Market in Asia-Pacific for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.2. Novel Antibody Therapies Market in Asia-Pacific for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.3. Novel Antibody Therapies Market in Asia-Pacific for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.4. Novel Antibody Therapies Market in Asia-Pacific for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.5. Novel Antibody Therapies Market in Asia-Pacific for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.6. Novel Antibody Therapies Market in Asia-Pacific for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.7. Novel Antibody Therapies Market in Asia-Pacific for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.8. Novel Antibody Therapies Market in Asia-Pacific for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.9. Novel Antibody Therapies Market in Asia-Pacific for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.10. Novel Antibody Therapies Market in Asia-Pacific for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.11. Novel Antibody Therapies Market in Asia-Pacific for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.12. Novel Antibody Therapies Market in Asia-Pacific for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 26.4. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Type of Therapy
  • 26.4.1. Novel Antibody Therapies Market in Asia-Pacific for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.2. Novel Antibody Therapies Market in Asia-Pacific for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.5. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Route of Administration
  • 26.5.1. Novel Antibody Therapies Market in Asia-Pacific for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.5.2. Novel Antibody Therapies Market in Asia-Pacific for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

• 27.1. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Drugs
  • 27.1.1. Novel Antibody Therapies Market in Middle East and North Africa for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.2. Novel Antibody Therapies Market in Middle East and North Africa for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.3. Novel Antibody Therapies Market in Middle East and North Africa for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.4. Novel Antibody Therapies Market in Middle East and North Africa for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.5. Novel Antibody Therapies Market in Middle East and North Africa for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.6. Novel Antibody Therapies Market in Middle East and North Africa for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.7. Novel Antibody Therapies Market in Middle East and North Africa for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.8. Novel Antibody Therapies Market in Middle East and North Africa for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.9. Novel Antibody Therapies Market in Middle East and North Africa for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 27.2. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Type of Novel Antibody
  • 27.2.1. Novel Antibody Therapies Market in Middle East and North Africa for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.2.2. Novel Antibody Therapies Market in Middle East and North Africa for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.2.3. Novel Antibody Therapies Market in Middle East and North Africa for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 27.3. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Target Indication
  • 27.3.1. Novel Antibody Therapies Market in Middle East and North Africa for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.2. Novel Antibody Therapies Market in Middle East and North Africa for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.3. Novel Antibody Therapies Market in Middle East and North Africa for PCALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.4. Novel Antibody Therapies Market in Middle East and North Africa for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.5. Novel Antibody Therapies Market in Middle East and North Africa for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.6. Novel Antibody Therapies Market in Middle East and North Africa for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.7. Novel Antibody Therapies Market in Middle East and North Africa for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.8. Novel Antibody Therapies Market in Middle East and North Africa for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.9. Novel Antibody Therapies Market in Middle East and North Africa for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.10. Novel Antibody Therapies Market in Middle East and North Africa for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.11. Novel Antibody Therapies Market in Middle East and North Africa for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.12. Novel Antibody Therapies Market in Middle East and North Africa for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 27.4. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Type of Therapy
  • 27.4.1. Novel Antibody Therapies Market in Middle East and North Africa for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.2. Novel Antibody Therapies Market in Middle East and North Africa for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.5. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Route of Administration
  • 27.5.1. Novel Antibody Therapies Market in Middle East and North Africa for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.5.2. Novel Antibody Therapies Market in Middle East and North Africa for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28. NOVEL ANTIBODY THERAPIES MARKET, BY LEADING PLAYERS

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. Novel Antibody Therapies Market: Distribution by Leading Companies
• 28.4. Data Triangulation and Validation

29. TABULATED DATA

30. LIST OF COMPANIES AND ORGANIZATIONS

관련자료